Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Paris  >  Sartorius Stedim Biotech    DIM   FR0013154002

SARTORIUS STEDIM BIOTECH (DIM)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

SARTORIUS STED BIO : Sartorius Stedim Biotech and c-LEcta sign sales agreement

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/03/2012 | 01:05pm CEST
SSB sells and distributes Serratia marcescens nuclease worldwide | Perfect addition to SSB´s purification product portfolio

Goettingen | Leipzig, Germany, May 3, 2012 - Sartorius Stedim Biotech, a leading international pharma and biotech supplier, and the biotechnology specialist c LEcta, announce the signing of a worldwide sales and distribution agreement for c LEcta's proprietary Serratia marcescens nuclease for biopharmaceutical applications. The German company specializes in the development of customized enzymes and production strains for industrial applications. Based on this agreement, customized endonuclease will now be available under the product name "Denarase" through all regular Sartorius Stedim Biotech sales channels.

Endonucleases are used in various biopharmaceutical production processes, such as in recombinant protein production, to remove nucleic acids, reduce viscosity levels and thus optimize process efficiencies. The company c-LEcta has optimized the production process for Serratia marcescens nuclease using a genetically engineered Bacillus strain to increase enzyme activity yields and remove endotoxins. As a result, this new technology enables the highest purity and quality nuclease to be produced.

"This endonuclease provides outstanding advantages from which our customers will benefit directly, such as cost efficiency and high performance," says Dr. Uwe Gottschalk, Vice President of Purification Technologies at Sartorius Stedim Biotech. "The nuclease is a perfect addition to our current purification product portfolio and supports our strategy as a total solution provider for the biopharmaceutical industry."

Dr. Marc Struhalla, Managing Director of c-LEcta comments, "The technology developed by c-LEcta allows us to provide nuclease to our customers in the highest quality. We are convinced that with Sartorius Stedim Biotech, we have found the right sales and distribution partner for the successful worldwide commercialization of our product."

About c-LEcta GmbH

c-LEcta is a German biotechnology company specializing in the development of customized enzymes and production strains for industrial applications. Patented technologies are employed for discovery and optimization of tailor-made enzymes and microbial strains. c-LEcta's know-how in microbiology and strain engineering allows efficient development of production strains for protein and small-molecule products. Proprietary technologies are used for the identification of new enzymes from biodiversity and for effective enzyme engineering.

distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SARTORIUS STEDIM BIOTECH
04/20SARTORIUS STEDIM BIOTECH SA : Change of the liquidity contract
EQ
04/18SARTORIUS STEDIM BIOTECH : and Penn State partner to advance teaching and resear..
AQ
04/18SARTORIUS STEDIM BIOTECH : and Penn State University announce partnership
AQ
04/16SARTORIUS STEDIM BIOTECH : and Penn State University announce partnership
PU
04/09SARTORIUS STEDIM BIOTECH : Ex-dividend day for for final dividend
FA
03/22SARTORIUS STEDIM BIOTECH : selected by ABL Europe to supply single-use process t..
AQ
03/21SARTORIUS STEDIM BIOTECH : supports ABL Europe to expand viral vector GMP capaci..
AQ
03/17SARTORIUS STEDIM BIOTECH : ABL Europe equips viral vector plant with Sartorius s..
AQ
03/16SARTORIUS STEDIM BIOTECH : unveils new ambr 250ht perfusion system for cell cult..
AQ
03/14SARTORIUS STEDIM BIOTECH : introduces new versions of data analytics software so..
AQ
More news
News from SeekingAlpha
02/22Sartorius Stedim Biotech (SDMHF) Investor Presentation - Slideshow 
01/31Sartorius Stedim Biotech 2017 Q4 - Results - Earnings Call Slides 
01/31Sartorius Stedim Biotech reports FY results 
2017Sartorius AG 2017 Q3 - Results - Earnings Call Slides 
2017Sartorius Stedim Biotech reports 1H results 
Financials (€)
Sales 2018 1 163 M
EBIT 2018 259 M
Net income 2018 184 M
Debt 2018 149 M
Yield 2018 0,66%
P/E ratio 2018 38,34
P/E ratio 2019 33,70
EV / Sales 2018 6,23x
EV / Sales 2019 5,59x
Capitalization 7 101 M
Chart SARTORIUS STEDIM BIOTECH
Duration : Period :
Sartorius Stedim Biotech Technical Analysis Chart | DIM | FR0013154002 | 4-Traders
Technical analysis trends SARTORIUS STEDIM BIOTECH
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Average target price 75,0 €
Spread / Average Target -3,4%
EPS Revisions
Managers
NameTitle
Joachim Kreuzburg Chairman, CEO, CFO & Head-Human Resources
Volker Niebel Executive VP-Operations & Information Technology
Oscar-Werner Reif Executive VP-Research & Development
Liliane de Lassus Independent Non-Executive Director
Bernard Lemaître Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
SARTORIUS STEDIM BIOTECH27.30%8 765
MEDTRONIC PLC-0.93%108 687
BAXTER INTERNATIONAL3.73%36 151
ZIMMER BIOMET HOLDINGS-8.58%22 366
ALIGN TECHNOLOGY11.20%22 204
TERUMO CORP15.06%21 478